Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724228 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
A Phase 2 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT02724228: Active Phase 2 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
NCT02724228 is a Phase 2 study of Achondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 30 participants, below the 148-participant average among 9 other Achondroplasia trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02724228, a Phase 2 study of Achondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
Primary Outcome
* Number of study participants with treatment-emergent adverse events. * Number of study participants with treatment-emergent serious adverse events
Conditions Studied
Interventions
- DRUG BMN 111
Study Locations (9)
California
- Children's Hospital & Research Center Oakland - Oakland
- Harbor - UCLA Medical Center - Torrance
Other
- Institut Necker - Paris
- Guys & St. Thomas NHS Foundation Trust Evelina Hospital - London
Illinois
- Ann and Robert H. Lurie Childrens Hospital of Chicago - Chicago
Maryland
- Johns Hopkins McKusick - Institute of Genetic Medicine - Baltimore
Tennessee
- Vanderbilt University - Nashville
Texas
- Baylor College of Medicine - Houston
Victoria
- Murdoch Children's Research Institute - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What the registry record for NCT02724228 still lists
NCT02724228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 148-participant average among 9 other Achondroplasia trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 1 intervention - of which BMN 111 is the first listed.
NCT02724228 lists 9 locations in 7 states (California, Other, Illinois).
Frequently Asked Questions
What is clinical trial NCT02724228 about?
NCT02724228 is a clinical study titled "A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)". This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed...
What is the current status of trial NCT02724228?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-01-26. Estimated completion is 2028-02.
What conditions does trial NCT02724228 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT02724228?
The interventions under investigation include: BMN 111 (DRUG).
Who is sponsoring clinical trial NCT02724228?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02724228 being conducted?
This trial has 9 study locations across California, Illinois, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02724228's enrollment target sits among peer trials
30 10th of 9 the lowest of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI